Nephrotoxicity Clinical Trial
Official title:
Occurrence and Economic Impact of Nephrotoxicity Associated With Vancomycin Exposure
The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to the hospital associated with these nephrotoxic events.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06360666 -
Clinical Outcomes in Adult Patients Undergoing Laparoscopic Surgery Under Neuraxial Anesthesia
|
||
Recruiting |
NCT01624324 -
Aminoglycoside Plasma Level Measurement in Neonates With Infection
|
N/A | |
Recruiting |
NCT03817970 -
Cisplatin Disposition and Kidney Injury
|
Phase 3 | |
Completed |
NCT01467154 -
Evaluation of Intravenous N-acetylcysteine to Prevent Contrast Media Induced Nephrotoxicity in an Emergency Center
|
N/A | |
Recruiting |
NCT03480971 -
Treatment of Radiation and Cisplatin Induced Toxicities With Tempol
|
Phase 2 | |
Recruiting |
NCT02528448 -
0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis
|
Phase 4 | |
Completed |
NCT02103855 -
Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06153147 -
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)
|
||
Completed |
NCT04354467 -
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
|
||
Recruiting |
NCT05673824 -
Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.
|
Phase 4 | |
Not yet recruiting |
NCT03438214 -
Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients
|
Phase 4 | |
Completed |
NCT03527160 -
Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
|
||
Completed |
NCT01848457 -
Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy
|
Phase 2 |